BAP1 and nonpapillary renal cell carcinoma: In addition, as in the 145 patients with primary ccRCC from the University of Texas Southwestern Medical Center, patients with BAP1-mutated tumors had a significantly higher probability of death (HR 2.8, 1.4–5.9; p = 0.004) and were associated with a higher grade (p = 0.095), necrosis (p = 0.038), and advanced pathologic tumor stage and clinical stage (p = 0.011 and p = 0.003, respectively), indicating that BAP1-mutant tumors were associated with poor outcome [9].